Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 6/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.48 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 5/20 | 0.45 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25067300 | 0.91 | FAAH (0.59) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL7646590 | 0.88 | FAAH (0.62) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL7650140 | 0.88 | FAAH (0.62) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL13811075 | 0.88 | FAAH (0.62) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL7647954 | 0.88 | FAAH (0.62) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL24684540 | 0.87 | FAAH (0.51) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL19662066 | 0.87 | FAAH (0.66) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL31683866 | 0.86 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL20856919 | 0.86 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2ENPP2 | |
| SCHEMBL28999762 | 0.86 | FAAH (0.65) | FAAHDNM1LPAR1LPAR2ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | FAAH 2862/4885DNM1 1891/4885LPAR1 4275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.